« Back
Home /
740 Y-P

740 Y-P

Item no.	HY-P0175-1mg
Manufacturer	MedChem Express
CASRN	1236188-16-1
Amount	1 mg
Quantity options	10 mMx1 mL 10 mg 1 mg 5 mg
Category	Cardiovascular Research Thrombosis & Hemostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Derossi D, et al. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide.\|[2]Xiaoli Feng, et al. Graphene Oxide Induces p62/SQSTM-dependent Apoptosis Through the Impairment of Autophagic Flux and Lysosomal Dysfunction in PC12 Cells. Acta Biomater. 2018 Nov;81:278-292.\|[3]Zhiqing Sun, et al. GABAB Receptor-Mediated PI3K/Akt Signaling Pathway Alleviates Oxidative Stress and Neuronal Cell Injury in a Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1513-1526. ACS Omega. 2022.\|Acta Biomater. 2018 Nov;81:278-292. \|Adv Sci (Weinh). 2025 Feb 14:e2410032.\|Aging (Albany NY). 2021 Sep 27;13(18):22502-22515.\|Am J Transl Res. 2021 Apr 15;13(4):2060-2076.\|Apoptosis. 2024 Jun 2.\|Apoptosis. 2024 Sep 6.\|Arch Biochem Biophys. 2023 May 22, 109645.\|Arch Dermatol Res. 2024 Dec 5;317(1):70.\|Arch Pharm Res. 2021 Jan 27.\|Biochem Biophys Res Commun. 2022 May 21;605:162-170.\|Biochem Biophys Res Commun. 2023 Jun 3.\|Biochem Biophys Res Commun. 2024 Apr 23:149983.\|Biochem Pharmacol. 2024 Nov 9:116620.\|Bioengineered. 2021 Nov 30.\|Bioengineered. 2022 Apr;13(4):10047-10060.\|Biol Reprod. 2023 Aug 21;ioad097.\|Biomaterials. 2019 Feb;194:57-72. \|Biomed Pharmacother. 2020 Nov;131:110689.\|Biomed Pharmacother. 2024 Oct 22:180:117560.\|bioRxiv. 2023 Mar 25.\|BMC Cancer. 2022 Jun 18;22(1):671.\|BMC Cancer. 2023 Jul 5;23(1):628.\|BMC Med. 2022 Dec 8;20(1):475.\|Bone Joint Res. 2025 Feb 6;14(2):97-110.\|Braz J Med Biol Res. 2024 Aug 19:57:e13796.\|Cancer Med. 2022 Nov 6.\|Cancers (Basel). 2023 Mar 28.\|Carbon. 2023 Jan 25, 217, 118617.\|Cell Biochem Biophys. 2024 Nov 16.\|Cell Biochem Biophys. 2024 Oct 14.\|Cell Biosci. 2019 Aug 27;9:68.\|Cell Commun Signal. 2020 Aug 24;18(1):131.\|Cell Death Dis. 2021 Sep 13;12(9):845.\|Cell Mol Life Sci. 2024 Mar 13;81(1):133.\|Cell Prolif. 2022 Sep 26;e13342.\|Cell Rep. 2021 Nov 16;37(7):110007.\|Cell Signal. 2020 Jul;71:109606.\|Cells. 2023 Jan 3;12(1):194.\|Chin Med. 2022 Sep 29;17(1):115.\|Clin Med Insights-On. 2021 May 5.\|Contrast Media Mol Imaging. 14 Jul 2022.\|Curr Med Sci. 2025 Mar 3.\|Curr Microbiol. 2025 Feb 3;82(3):110.\|Cytokine. 2021 Dec 1;150:155776.\|Cytotechnology. 2025 Apr;77(2):77.\|Dis Markers. 02 Sep 2021.\|Drug Dev Res. 2022 Apr 26.\|Drug Dev Res. 2022 Sep 6.\|Drug Resist Updat. 2024 Dec 3:78:101179.\|Epigenetics. 2023 Dec;18(1):2239607.\|Eur J Pharmacol. 2023 Jun 26;175863.\|Eur J Pharmacol. 2024 Feb 7:968:176401.\|Eur J Pharmacol. 2024 Sep 10:176824.\|Eur J Pharmacol. 2024 Sep 10:176991.\|Exp Cell Res. 2019 Dec 15;385(2):111691.\|Exp Eye Res. 2022 Nov 24;109335.\|Exp Mol Med. 2023 May 1.\|Exp Ther Med. July 15, 2021.\|Fish Shellfish Immunol. 2021 Dec 28;120:648-657.\|Free Radic Biol Med. 2023 Oct 10;209(Pt 1):55-69.\|Front Biosci (Landmark Ed). 2024 Aug 19;29(8):289.\|Front Pharmacol. 2020 Feb 25;11:114. \|Front Pharmacol. 2021 Jul 15;12:667644.\|Gene Ther. 2024 Sep 21.\|Genes (Basel). 2023 Apr 20, 14(4), 944.\|Genes Dis. 1 July 2021.\|Genomics. 2023 May 5;110636.\|Glia. 2022 Nov 23.\|Heliyon. 2024 Aug 20;10(17):e36579.\|Heliyon. 2024 Jul 10;10(14):e34397.\|Heliyon. 2024 July 10.\|Heliyon. 2024 Jun 10;10(12):e32802.\|Heliyon. 2024 May 31.\|In Vitro Cell Dev Biol Anim. 2022 Jun 15.\|Inflammopharmacology. 2022 Nov 19.\|Int Immunopharmacol. 2023 Jul 9;122:110579.\|Int Immunopharmacol. 2023 Sep 5;124(Pt A):110876.\|Int Immunopharmacol. 2024 Apr 15:133:112005.\|Int Immunopharmacol. 2024 Jul 26:139:112717.\|Int Immunopharmacol. 2024 May 17:134:112241.\|Int Immunopharmacol. 2025 Feb 28:151:114352.\|Int J Biol Macromol. 2023 Jun 13;125373.\|Int J Biol Macromol. 2024 Sep 10:135547.\|Int J Biol Macromol. 2025 Jan 10:139766.\|Int J Mol Med. 2021 Feb;47(2):688-698.\|Int J Mol Med. 2021 May;47(5):67.\|Int J Mol Med. 2023 May;51(5):40.\|Int J Mol Sci. 2023 May 19, 24(10), 9000.\|Int J Mol Sci. 2024 Dec 25;26(1):84.\|Int J Oncol. 2021 May 14.\|Int J Oncol. 2021 May;58(5):23.\|Ir J Med Sci. 2022 May 4.\|iScience. 2024 Jan 12\|J Agric Food Chem. 2022 Dec 21;70(50):15804-15817.\|J Cell Mol Med. 2024 Jul;28(13):e18386.\|J Cell Physiol. 2024 Mar 22.\|J Clin Invest. 2022 Nov 22;e153470.\|J Clin Lab Anal. 2022 Nov 8;e24720.\|J Dairy Sci. 2022 Feb 2;S0022-0302(22)00059-5.\|J Ethnopharmacol. 2021 Aug 11;281:114438.\|J Ethnopharmacol. 2023 Dec 27:117628.\|J Ethnopharmacol. 2024 Jan 20:117768.\|J Ethnopharmacol. 2024 Oct 4:118910.\|J Ethnopharmacol. 2025 Jan 18:119381.\|J Exp Clin Cancer Res. 2020 Jun 30;39(1):123.\|J Exp Clin Cancer Res. 2021 Aug 12;40(1):255.\|J Funct Foods. 2023 Oct, 109, 105770.\|J Headache Pain. 2022 Aug 10;23(1):98.\|J Hepatocell Carcinoma. 2021 Nov 3;8:1323-1338.\|J Mol Histol. 2023 Sep 30.\|J Nutr Biochem. 2021 Oct 13;108882.\|J Nutr Biochem. 2024 Jul 16:109702.\|J Pharm Pharmacol. 2022 Jul 5;rgac047.\|J Transl Med. 2021 Feb 10;19(1):62.\|J Transl Med. 2023 Nov 16;21(1):817.\|J Transl Med. 2024 Nov 29;22(1):1085.\|Korean J Physiol Pharmacol. 2022 Nov 1;26(6):541-556.\|Life Sci. 2021 Jan 25;119107.\|Life Sci. 2019 Sep 15;233:116696.\|Mater Today Bio. 2022 Jul 1;16:100344.\|Mol Biol Rep. 2022 Nov 12.\|Mol Cancer. 2022 May 10;21(1):112.\|Mol Cell Biochem. 2022 Apr 1.\|Mol Cell Biochem. 2022 Feb 19.\|Mol Cell Proteomics. 2023 Jul 31;100628.\|Mol Med Rep. 2021 Jan;23(1):76.\|Mol Med. 2023 Oct 3;29(1):133.\|Mol Neurobiol. 2024 Sep 23.\|Nat Commun. 2024 Sep 12;15(1):7996.\|Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug 9.\|Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528.\|Noncoding RNA Res. 2024 Nov 12.\|Onco Targets Ther. 2019 Dec 4;12:10639-10650.\|Oncol Lett. 2023 Apr 13, 25(6): 224.\|Oncol Lett. 2023 Nov 15.\|Oncol Lett. September 28, 2021.\|Oncol Rep. 2020 Mar;43(3):919-929.\|Oncol Rep. 2021 Mar 16.\|Oncol Rep. 2022 Oct;48(4):169.\|OncoTargets and Therapy Dovepress. 2019 Oct 16;12:8537-8552.\|Oral Dis. 2024 Jan 15.\|Oxid Med Cell Longev. 2021 Mar 31.\|Pathol Res Pract. 2023 Jul 27, 154717.\|Pharm Biol. 2022 Dec;60(1):75-86.\|Phytomedicine. 2023 May 13, 154873.\|Phytomedicine. 2023 Sep 22, 155117.\|Phytomedicine. 2025 Feb 14.\|Phytomedicine. 28 July 2022, 154360.\|Phytomedicine. May 2022, 154014.\|Phytother Res. 2023 Apr 28.\|Phytother Res. 2024 May 2.\|PLoS One. 2024 Oct 16;19(10):e0311419.\|PLoS One. 2024 Sep 27;19(9):e0311143.\|Research Square Preprint. 2023 Apr 13.\|Research Square Preprint. 2023 Aug 10.\|Research Square Preprint. 2024 Mar 25.\|Research Square Preprint. 2024 May 2.\|Research Square Print. 2022 May.\|Respir Physiol Neurobiol. 2020 Oct;281:103496.\|Sci Rep. 2021 Sep 29;11(1):19268.\|Sci Rep. 2023 Jul 21;13(1):11795.\|Sci Rep. 2024 Aug 30;14(1):20231.\|Sci Rep. 2024 Sep 5;14(1):20802.\|Sci Rep. 2025 Mar 20;15(1):9644.\|Sci Rep. 2025 Mar 4;15(1):7639.\|Technol Cancer Res Treat. Jan-Dec 2020;19:1533033820957023. \|Theranostics. 2024 Jul 8;14(11):4278-4296.\|Toxicol Appl Pharmacol. 2020 Dec 15;409:115335.\|Toxicol Appl Pharmacol. 9 March 2022, 115971.\|Toxicol In Vitro. 2022 Apr;80:105328.\|Tradit Med Res. 2020 May.\|Viruses. 2023 Jul 28, 15(8), 1646.\|World J Gastrointest Oncol. 2023 Oct 15.\|BMC Complement Med Ther. 2023 Aug 22;23(1):295.
Smiles	C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=2C=3C(NC2)=CC=CC3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CC4=CC=C(OP(=O)(O)O)C=C4)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCSC)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC(O)=O)=O)CO)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCSC)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCC(N)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCCCN)=O)[C@H](CC)C)=O)C=5C=6C(NC5)=CC=CC6
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	740YPDGFR,PDGFR 740Y-P
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; PI3K
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Molecular Weight	3270.70
Product Description	740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone[1].
Manufacturer - Research Area	Cancer
Solubility	H2O: 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; PI3K/Akt/mTOR
Isoform	PI3K
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P0175-1mg-safety-datasheet.pdf